RxDoctor Payments Data

Lisa Clough, MD

Infectious Disease · Kansas City, KSNPI 1780787697

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $164 of the $194 with a category attached, or 84.9%. 4 manufacturers reported payments, led by Gilead at 53.4% of the total. Reporting peaked in 2023 at $103 and has fallen 52.0% since, to $50 in 2024. That places this record below the midpoint for infectious disease clinicians in KS, where the typical reported total is $211.

$194in general payments, 2019–2025

Across 6 payments — averaging $32.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$103
  • Viiv Healthcare Company$50
  • Merck$29
  • AbbVie$11
$680,441in research payments, 2019–2025

Across 110 payments — averaging $6185.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$266K
  • Merck$265K
  • Astellas Pharma Global Development$130K
  • La Jolla Pharmaceutical Company$17K
  • Emergent Biosolutions Inc.$1K
  • AbbVie$745

What the payments were for

  • Food & beverage$16485%
  • Education$2915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead1$103
Viiv Healthcare Company1$50
Merck3$29
AbbVie1$11

How this compares

$194 in reported general payments places this provider in the 45th percentile of 56 infectious disease providers in Kansas.

See all infectious disease providers in Kansas

Medicare billing

Part B allowed, 2024
$55,886
Medicare patients
137
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala69$290,241
TriumeqAbacavir/Dolutegravir/Lamivudi66$252,548
TivicayDolutegravir Sodium61$134,817
PrezcobixDarunavir/Cobicistat44$111,723
DescovyEmtricitabine/Tenofov Alafenam49$107,442
DovatoDolutegravir Sodium/Lamivudine30$86,655
CabenuvaCabotegravir/Rilpivirine12$75,287
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$55,572
IsentressRaltegravir Potassium19$40,128
PifeltroDoravirine13$25,633
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$9,069
Efavirenz13$1,040
Doxycycline Hyclate28$569
Amoxicillin24$207
Cephalexin11$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Cabenuva$50$549,306169 claims
GileadBiktarvy, Descovy$103$397,683118 claims
MerckIsentress, Pifeltro$29$65,76132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 56 infectious disease providers in Kansas.

Other infectious disease in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →